Data from Revisit of Field Cancerization in Squamous Cell Carcinoma of Upper Aerodigestive Tract: Better Risk Assessment with Epigenetic Markers

Authors:
  • YLYi-Chia Lee
    Yi-Chia Lee
  • HWHsiu-Po Wang
    Hsiu-Po Wang
  • CWCheng-Ping Wang
    Cheng-Ping Wang
  • JKJenq-Yuh Ko
    Jenq-Yuh Ko
  • JLJang-Ming Lee
    Jang-Ming Lee
  • HCHan-Mo Chiu
    Han-Mo Chiu
  • JLJaw-Town Lin
    Jaw-Town Lin
  • SYSatoshi Yamashita
    Satoshi Yamashita
  • DODaiji Oka
    Daiji Oka
  • NWNaoko Watanabe
    Naoko Watanabe
  • YMYasunori Matsuda
    Yasunori Matsuda
  • TUToshikazu Ushijima
    Toshikazu Ushijima

Abstract
We quantified field cancerization of squamous cell carcinoma in the upper aerodigestive tract with epigenetic markers and evaluated their performance for risk assessment. Methylation levels were analyzed by quantitative methylation-specific PCR of biopsied specimens from a training set of 255 patients and a validation set of 224 patients. We also measured traditional risk factors based on demographics, lifestyle, serology, genetic polymorphisms, and endoscopy. The methylation levels of four markers increased stepwise, with the lowest levels in normal esophageal mucosae from healthy subjects without carcinogen exposure, then normal mucosae from healthy subjects with carcinogen exposure, then normal mucosae from cancer patients, and the highest levels were in cancerous mucosae (P < 0.05). Cumulative exposure to alcohol increased methylation of homeobox A9 in normal mucosae (P < 0.01). Drinkers had higher methylation of ubiquitin carboxyl-terminal esterase L1 and metallothionein 1M (P < 0.05), and users of betel quid had higher methylation of homeobox A9 (P = 0.01). Smokers had increased methylation of all four markers (P < 0.05). Traditional risk factors allowed us to discriminate between patients with and without cancers with 74% sensitivity (95% CI: 67%–81%), 74% specificity (66%–82%), and 80% area under the curve (67%–91%); epigenetic markers in normal esophageal mucosa had values of 74% (69%–79%), 75% (67%–83%), and 83% (79%–87%); and both together had values of 82% (76%–88%), 81% (74%–88%), and 91% (88%–94%). Epigenetic markers done well in the validation set with 80% area under the curve (73%–85%). We concluded that epigenetics could improve the accuracies of risk assessment. Cancer Prev Res; 4(12); 1982–92. ©2011 AACR.